Editas Medicine appoints Elliot Levy, M.D. as independent director

Editas Medicine, Inc.

Dr. Levy appointed as class I director; Board size increased by one member effective April 11, 2023.
He will serve on the Audit Committee and Science and Technology Committee.
Levy is a Venture Partner at 5AM Ventures; former SVP of R&D at Amgen; boards of Omega Therapeutics and NuCana.
Annual cash compensation: $40,000 board + $7,500 Audit + $5,000 Science & Tech; option for 50,000 shares vesting over 3 years.
No arrangement or understanding with any other person pursuant to which he was selected.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Elliot Levy

Independent Director

EDIT · Editas Medicine, Inc.

Effective: 2023-04-11
Filed: April 13, 2023, 7:59 PM ET

appointed Elliot Levy, M.D. as an independent director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Elliot Levy was appointed as Independent Director at Editas Medicine, Inc..

Action: appointed
Role: Independent Director

Exact text from the filing

appointed Elliot Levy, M.D. as an independent director, effective immediately.

View on SEC.gov

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-005886

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.